Table 2 Patient demographics and baseline disease characteristics (Phase 3 trial)¹

Patients, n

210

210

210

Age in years, mean (SD)

37.5 (13.9)

38.2 (15.1)

40.7 (14.2)

Sex, (male: female)

40%: 60%

36%: 64%

39%: 61%

Ethnicity, n (%):

 Caucasian

107 (51)

102 (49)

98 (47)

 Black

12 (6)

13 (6)

20 (10)

 Hispanic

90 (43)

92 (44)

89 (42)

 Other

1 (<1)

3 (<2)

3 (<2)

AR duration in years, mean (SD)

17.4 (11.9)

18.6 (11.5)

18.9 (11.5)

Baseline DNSS, mean (SD)^a

2.16 (0.43)

2.17 (0.41)

2.22 (0.42)